My current research interests are chemical mutagenesis and isolation of secondary metabolites from important fungi and their bioactive potential. This strategy has been recently introduced to fungi, i.e., a mutation-based mutagenesis strategy for the discovery of novel bioactive compounds from silent pathways of fungal secondary metabolites. By using chemical mutagenesis, we identified a new array of molecules and enhanced the yield of important metabolites, which were not produced by the fungi in normal media conditions. (Read Vidushi's article DOI: 10.1021/acschembio.7b00875.) My research operates at the interface of chemistry and biology, where I am applying bioorthogonal and photochemistries to establish tools uniquely capable of sampling the heterogeneous and dynamic nature of biology. Using a photocaged noncanonical amino acid, I have created a technique to label newly synthesized cellular proteins selectively at user-defined points in time and space for isolation and downstream proteomic analysis. I expect this tool to facilitate an enhanced understanding of biology by shedding light on the 4D proteomic changes that accompany disease and development. Combining this knowledge with the aforementioned chemistries, I am also interested in engineering next-generation biomaterials that recapitulate native biological complexity. These advances hold promise for the development of diagnostic tools and treatments for disease, as well as toward the continued advancement of variegated biomaterials for regenerative medicine applications.
My research operates at the interface of chemistry and biology, where I am applying bioorthogonal and photochemistries to establish tools uniquely capable of sampling the heterogeneous and dynamic nature of biology. Using a photocaged noncanonical amino acid, I have created a technique to label newly synthesized cellular proteins selectively at user-defined points in time and space for isolation and downstream proteomic analysis. I expect this tool to facilitate an enhanced understanding of biology by shedding light on the 4D proteomic changes that accompany disease and development. Combining this knowledge with the aforementioned chemistries, I am also interested in engineering next-generation biomaterials that recapitulate native biological complexity. These advances hold promise for the development of diagnostic tools and treatments for disease, as well as toward the continued advancement of variegated biomaterials for regenerative medicine applications. (Read Steven's article DOI: 10.1021/acschembio.7b01023.)
■ GLORIA ANDOLINA My Ph.D. research focused on gaining a better understanding of the interaction of a new class of antibacterial peptidomimetic (AMP) with the outer membrane protein LptD. The target protein is responsible for the transport of LPS to the surface in Gram-negative bacteria, and the novel AMP inhibits the biosynthesis of the outer membrane in P. aeruginosa. Our paper highlights the unicity of the LptD structure in P. aeruginosa and describes the work that was necessary to identify the binding site of the AMPs, including experiments of photoaffinity labeling, mass spectroscopy, and binding studies. Nonscientific Interests: Cricket, reading history of religion and philosophy, chess, and walking Natural products have been a valuable source of chemicals for drug discovery. My research focuses on drug discovery from natural sources with overall objectives to build a library of compounds for screening to identify natural leads. Experimental designs include extraction, enrichment, and purification using different chromatographic techniques, including HPLC, dereplication, and identification of metabolites by using LC-MS, MS-MS, and complete structural elucidation by detailed 2D NMR studies. Although we were able to find some natural preclinical lead molecules for further drug discovery using conventional biological screening, the current project focuses on screening using LC-MS to discover quorum-sensing inhibitors, using real-time identification and quantification of biomarkers with HRMS and MRM. A significant quantitative change in the production of biomarkers in Pseudomonas aeruginosa PAO1 was observed in the presence of capsaicin and 6-gingerol, correlating with antiquorum-sensing properties of molecules. This study demonstrates LC-MS as a tool for screening and discovering quorum-sensing inhibitors. Nonscientific Interests: Cooking, coffee tasting, and movies I'm interested in exploring combined therapeutic strategies in cancer, specifically for MAPK inhibitors to achieve durable pathway inhibition and better antitumor efficacy. My current research focuses on understanding the SHP2 biology in cancer, particularly its role in mediating feedback activation in RAS mutant cancers following treatment of MAPK inhibitors. In this article, we identified a second, distinct small molecule allosteric site on SHP2 and showed that simultaneous occupation of both allosteric sites could cooperatively enhance the MAPK pathway inhibition. Our work illustrates an example of dual allosteric targeted protein inhibition and enables our effort to further interrogate the functional role of SHP2 in cancer. (Read Hengyu's article DOI: 10.1021/acschembio.7b00980.) My graduate research focused on the development of specific and multivalent antagonists against DC-SIGN, a C-type lectin receptor (CLR) that modulates the immune response. Some CLRs are hijacked by viral and bacterial carbohydrate-based pathogens. Thus, the design of ligands able to target specifically one CLR has potential value in therapeutic design. Selectively blocking DC-SIGN, being notably involved in HIV transinfection of T lymphocytes, without interfering with Langerinmediated HIV clearance seems to be a challenging task due to their overlapping carbohydrate specificity. By studying both lectin-binding sites, however, a rational-differential approach has been exploited to design, synthesize, and tightly characterize a highly selective glycomimetic for DC-SIGN. Additionally to this work, we investigated multivalent scaffolds with different valences as well as ligand presentation in space to improve the affinity and thereby to compete with the HIV gp120 binding. 
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